CCD

MHI Contributes to Successful Acquisition of First Observation Images by JAXA's "XRISM" X-ray Imaging and Spectroscopy Mission Satellite

Retrieved on: 
Friday, February 9, 2024

MHI technology supported the data acquisition of the distribution and chemical composition of high-temperature plasma weaving through the galaxies by the XRISM satellite's onboard soft X-ray imager (Xtend) and soft X-ray spectrometer (Resolve).

Key Points: 
  • MHI technology supported the data acquisition of the distribution and chemical composition of high-temperature plasma weaving through the galaxies by the XRISM satellite's onboard soft X-ray imager (Xtend) and soft X-ray spectrometer (Resolve).
  • XRISM's mission is to document, in unprecedented detail, the formation of stars, galaxies and galaxy clusters.
  • MHI, which serves as manufacturer of the mission instruments, is responsible for designing and manufacturing Xtend's X-ray charge coupled devices (CCD) (Note2) detector and the data processors for Xtend and Resolve.
  • The mission data processors employed on both Xtend and Resolve are "SOI-SOC2" satellite-mounted microprocessor units (MPUs) jointly developed by JAXA and MHI.

Daré Bioscience to Present at the Sexual Medicine Society of North America (SMSNA) 24th Annual Fall Scientific Meeting

Retrieved on: 
Monday, November 13, 2023

“The comprehensive Phase 2b RESPOND study data represent an important milestone in the field of female sexual dysfunction,” said Dr. Andrew Goldstein, Medical Advisor for Daré Bioscience and former President of The International Society for the Study of Women's Sexual Health (ISSWSH).

Key Points: 
  • “The comprehensive Phase 2b RESPOND study data represent an important milestone in the field of female sexual dysfunction,” said Dr. Andrew Goldstein, Medical Advisor for Daré Bioscience and former President of The International Society for the Study of Women's Sexual Health (ISSWSH).
  • Sildenafil Cream is an investigational, proprietary topical cream formulation specifically designed to be used on-demand at the time of sexual activity to increase blood flow to the genital tissue in women.
  • "These additional data from the Phase 2b RESPOND study, which demonstrated improvements in a broader population of women, underscore the meaningful potential for Sildenafil Cream in women's sexual health.
  • There is a critical unmet need for a safe, effective and ‘on demand' solution to difficulties with sexual arousal."

IMAT Solutions Achieves Annual Recertification of Validated Data Stream Designation in NCQA Data Aggregator Validation Program

Retrieved on: 
Wednesday, December 13, 2023

PLEASANT GROVE, Utah, Dec. 13, 2023 /PRNewswire-PRWeb/ -- IMAT Solutions, a leader in delivering innovative, real-time, healthcare data management and population health reporting solutions, announced today that it has earned its annual recertification of its Validated Data Stream designation in the National Committee for Quality Assurance (NCQA) Data Aggregator Validation (DAV) program in November 2023.

Key Points: 
  • Validated Data Flows Promote Trust, Support Value-Based Contracting, Ease Quality Measurement Loads
    PLEASANT GROVE, Utah, Dec. 13, 2023 /PRNewswire-PRWeb/ -- IMAT Solutions , a leader in delivering innovative, real-time, healthcare data management and population health reporting solutions, announced today that it has earned its annual recertification of its Validated Data Stream designation in the National Committee for Quality Assurance (NCQA) Data Aggregator Validation (DAV) program in November 2023.
  • "Our ongoing recertification of NCQA Data Aggregator Validation designation reinforces how our platform improves the usability and quality of clinical data for payers and providers," said Kurt Garbe, CEO of IMAT Solutions.
  • "Our ongoing recertification of NCQA Data Aggregator Validation designation reinforces how our platform improves the usability and quality of clinical data for payers and providers," said Kurt Garbe, CEO of IMAT Solutions.
  • As a result, no primary source verification is required for HEDIS reporting when health plans report data from Data Aggregator Validation validated sources.

DrTalks Announces the Silent Killers Summit for Chronic Inflammatory Diseases Taking Place from February 20 - 26, 2024

Retrieved on: 
Thursday, November 30, 2023

CARLSBAD, Calif., Nov. 30, 2023 /PRNewswire/ -- DrTalks has recently announced the Silent Killers - Reversing the Root Cause of Chronic Inflammatory Disease Summit. It's a virtual event that aims to help individuals uncover the root causes of their health challenges, taking place from February 20 to 26, 2024. Hosted by Laura Frontiero, FNP-BC, CCD, this event equips attendees with the knowledge and tools essential for overcoming lethal diseases by addressing their underlying causes.

Key Points: 
  • This online event delves deep into the heart of chronic inflammatory diseases, exploring often overlooked causes such as parasites and toxins.
  • The Silent Killers Summit is free for all attendees and is taking place from February 20 - 26, 2024.
  • CARLSBAD, Calif., Nov. 30, 2023 /PRNewswire/ -- DrTalks has recently announced the Silent Killers - Reversing the Root Cause of Chronic Inflammatory Disease Summit .
  • It's a virtual event that aims to help individuals uncover the root causes of their health challenges, taking place from February 20 to 26, 2024.

PetPace to Partner with Veterinary Health Research Centers to Pioneer Canine Alzheimer's Research Using Advanced Smart Collars

Retrieved on: 
Wednesday, November 22, 2023

BURLINGTON, Mass., Nov. 22, 2023 /PRNewswire-PRWeb/ -- PetPace, a leader in pet health monitoring technology, is excited to announce a groundbreaking collaboration with the Veterinary Health Research Centers (VHRC) to spearhead research on Canine Alzheimer's Disease. This initiative, named the Dogs Overcoming Geriatric Memory and Aging (DOGMA) Study, will leverage PetPace's cutting-edge biometric collars to monitor and analyze the health and behavior of aging dogs, shedding light on the parallels between Canine Cognitive Decline (CCD) and Alzheimer's Disease (AD) in humans.

Key Points: 
  • PetPace, a leader in pet health monitoring technology, is excited to announce a groundbreaking collaboration with the Veterinary Health Research Centers (VHRC) to spearhead research on Canine Alzheimer's Disease.
  • BURLINGTON, Mass., Nov. 22, 2023 /PRNewswire-PRWeb/ -- PetPace, a leader in pet health monitoring technology, is excited to announce a groundbreaking collaboration with the Veterinary Health Research Centers (VHRC) to spearhead research on Canine Alzheimer's Disease.
  • PetPace CEO, Lior Abraham, stated, "At PetPace, we are committed to advancing the well-being of pets through innovative technology.
  • PetPace is widely regarded as the most advanced AI smart collar for continuously monitoring the health and well-being of dogs, in addition to offering GPS location tracking solutions.

Abingworth raises $356 million for new Clinical Co-Development Co-Investment Fund (CCD-CIF)

Retrieved on: 
Monday, October 30, 2023

Abingworth Clinical Co-Development Co-Investment Fund (CCD-CIF) was significantly oversubscribed, exceeding its target of $300 million.

Key Points: 
  • Abingworth Clinical Co-Development Co-Investment Fund (CCD-CIF) was significantly oversubscribed, exceeding its target of $300 million.
  • Alongside the Abingworth Clinical Co-Development Fund 2 (ACCD 2), a fund of $583 million, Abingworth has raised over $930 million in new funds since 2021 to invest in the development of late-stage clinical programs from pharmaceutical and biotechnology companies in the US, UK, Europe, and Asia-Pacific, and create innovative therapeutics with potential to significantly improve human health.
  • Abingworth pioneered the clinical co-development (CCD) investment strategy in 2009, investing initially via its venture funds and then through its first dedicated fund, Abingworth Clinical Co-Development Fund (ACCD 1), which launched in 2016 raising $109 million.
  • Overall, across all strategies – venture, growth, and clinical co-development – Abingworth has invested in over 185 life sciences companies over the last 50 years.

Global X-Ray Detector Market to Reach $6.22 Billion by 2023, Growing at a CAGR of 6.02% - ResearchAndMarkets.com

Retrieved on: 
Thursday, November 2, 2023

By Application: The market report categorizes the x-ray detector market into four main applications: Medical, Industrial, Security, and Veterinary.

Key Points: 
  • By Application: The market report categorizes the x-ray detector market into four main applications: Medical, Industrial, Security, and Veterinary.
  • By Technology: X-ray detector technology is segmented into four categories: Flat panel detector, computed radiography, line scan detector, and CCD detector.
  • The global x-ray detector market is divided into five major regions: Asia Pacific, North America, Europe, Latin America, and Middle East & Africa.
  • Growing Geriatric Population: The increasing elderly population drives the demand for medical imaging procedures, contributing to the growth of the x-ray detector market.

Camera Modules Market worth $68.5 billion by 2028 - Exclusive Report by MarketsandMarkets™

Retrieved on: 
Tuesday, September 19, 2023

The adoption of camera modules in advanced driver assistance systems (ADAS) with the growing trend for autonomous vehicles provides opportunities for market growth.

Key Points: 
  • The adoption of camera modules in advanced driver assistance systems (ADAS) with the growing trend for autonomous vehicles provides opportunities for market growth.
  • The adoption of advanced camera modules to assist the driver in preventing collisions and provide an enhanced driving experience is set to push market growth.
  • Asia Pacific will hold the largest share of the camera modules market throughout the forecast period.
  • The camera modules market in the Asia Pacific region is poised for rapid growth driven by several key factors.

Camera Modules Market worth $68.5 billion by 2028 - Exclusive Report by MarketsandMarkets™

Retrieved on: 
Tuesday, September 19, 2023

The adoption of camera modules in advanced driver assistance systems (ADAS) with the growing trend for autonomous vehicles provides opportunities for market growth.

Key Points: 
  • The adoption of camera modules in advanced driver assistance systems (ADAS) with the growing trend for autonomous vehicles provides opportunities for market growth.
  • The adoption of advanced camera modules to assist the driver in preventing collisions and provide an enhanced driving experience is set to push market growth.
  • Asia Pacific will hold the largest share of the camera modules market throughout the forecast period.
  • The camera modules market in the Asia Pacific region is poised for rapid growth driven by several key factors.

Hyperspectral Remote Sensing Market size to increase by USD 85.6 million during 2022-2027 | Growing adoption of UAVs to drive the growth - Technavio

Retrieved on: 
Tuesday, September 12, 2023

NEW YORK, Sept. 12, 2023 /PRNewswire/ -- The hyperspectral remote sensing market size is expected to grow by USD 85.6 million between 2022 and 2027.

Key Points: 
  • NEW YORK, Sept. 12, 2023 /PRNewswire/ -- The hyperspectral remote sensing market size is expected to grow by USD 85.6 million between 2022 and 2027.
  • The growing adoption of UAVs drives the market growth.
  • Hence, such factors drive the growth of the hyperspectral remote sensing market during the forecast period.
  • The report analyses the market size and growth and provides accurate predictions on the growth of the market.